A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

Rohit Mehra, Yang Shi, Aaron M. Udager, John R. Prensner, Anirban Sahu, Matthew K. Iyer, Javed Siddiqui, Xuhong Cao, John Wei, Hui Jiang, Felix Y. Feng, Arul M. Chinnaiyan

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.

Original languageEnglish (US)
Pages (from-to)1121-1127
Number of pages7
JournalNeoplasia (United States)
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Long Noncoding RNA
Prostatectomy
In Situ Hybridization
Prostatic Neoplasms
RNA
Castration
Neoplasms
Biomarkers
Regression Analysis
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research

Cite this

A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. / Mehra, Rohit; Shi, Yang; Udager, Aaron M.; Prensner, John R.; Sahu, Anirban; Iyer, Matthew K.; Siddiqui, Javed; Cao, Xuhong; Wei, John; Jiang, Hui; Feng, Felix Y.; Chinnaiyan, Arul M.

In: Neoplasia (United States), Vol. 16, No. 12, 01.12.2014, p. 1121-1127.

Research output: Contribution to journalArticle

Mehra, Rohit ; Shi, Yang ; Udager, Aaron M. ; Prensner, John R. ; Sahu, Anirban ; Iyer, Matthew K. ; Siddiqui, Javed ; Cao, Xuhong ; Wei, John ; Jiang, Hui ; Feng, Felix Y. ; Chinnaiyan, Arul M. / A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. In: Neoplasia (United States). 2014 ; Vol. 16, No. 12. pp. 1121-1127.
@article{6fdab11a67b4495e9e8c6873c6ad20a9,
title = "A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer",
abstract = "Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.",
author = "Rohit Mehra and Yang Shi and Udager, {Aaron M.} and Prensner, {John R.} and Anirban Sahu and Iyer, {Matthew K.} and Javed Siddiqui and Xuhong Cao and John Wei and Hui Jiang and Feng, {Felix Y.} and Chinnaiyan, {Arul M.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.neo.2014.11.006",
language = "English (US)",
volume = "16",
pages = "1121--1127",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

AU - Mehra, Rohit

AU - Shi, Yang

AU - Udager, Aaron M.

AU - Prensner, John R.

AU - Sahu, Anirban

AU - Iyer, Matthew K.

AU - Siddiqui, Javed

AU - Cao, Xuhong

AU - Wei, John

AU - Jiang, Hui

AU - Feng, Felix Y.

AU - Chinnaiyan, Arul M.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.

AB - Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.

UR - http://www.scopus.com/inward/record.url?scp=85003318605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003318605&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2014.11.006

DO - 10.1016/j.neo.2014.11.006

M3 - Article

C2 - 25499224

AN - SCOPUS:85003318605

VL - 16

SP - 1121

EP - 1127

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 12

ER -